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PENILAIAN IMPAK PENJAGAAN FARMASEUTIKAL KE ATAS PESAKIT
DIABETES MELLITUS YANG BARU DIDIAGNOS DI HOSPITAL
PENJAGAAN TERTIAR DI BANDAR SUB METROPOLITAN NEPAL BARAT
ABSTRAK
Status sosioekonomi yang buruk dan kekurangan pengetahuan adalah kekangan utama
yang perlu ditangani dalam pengurusan penyakit diabetes terutama dalam negara miskin.
Oleh itu, satu kajian klinikal kawalan rawak telah dilaksanakan dalam 5 fasa dengan
objektif untuk menilai impak intervensi penjagaan farmaseutikal ke atas tahap
pengetahuan, sikap dan praktis (KAP), kualiti hidup berkaitan kesihatan (HRQoL),
kepatuhan pengambilan ubat dan hasil akhir klinikal, kos penjagaan kesihatan langsung
dan kepuasan pesakit diabetes mellitus yang baru didiagnos di hospital penjagaan tertiar.
Satu sampel pesakit seramai 162 orang telah dipilih dari Julai 2010 sehingga Disember
2010 dan dirawak dengan cara 1:1:1 dalam tiga kumpulan selari: kumpulan kawalan (n=
54), kumpulan ujian 1 (n= 54) dan kumpulan ujian 2 (n= 54). Intervensi telah dijalankan
menggunakan bahan dan alat pendidikan yang direka khas. Ujian Kruskal-Wallis, Mann-
Whitney U, Friedman and Wilcoxon signed rank (p≤0.05) telah digunakan untuk
mencari perbezaan manakala ujian korelasi Spearman (p≤0.05) telah digunakan untuk
mencari hubungkait antara pembolehubah bersandar dan tak bersandar. Umur,
pendapatan bulanan, jantina, pendidikan dan pekerjaan pesakit didapati berkaitan secara
signifikan dengan skor pengetahuan, sikap dan praktis tentang diabetes dan
pengurusannya. Skor HRQoL dan kepuasan didapati berkaitan secara negatif dengan
umur mereka manakala umur, pendidikan dan pekerjaan pesakit adalah faktor peramal
yang signifikan bagi kepatuhan pengambilan ubat.  Pada tahap asas, pesakit mempunyai
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pengetahuan dan praktis yang buruk tetapi secara relatif mempunyai sikap yang lebih
baik tentang diabetes dan mereka menganggap kualiti hidup masa sekarang adalah
buruk. Kepatuhan pesakit terhadap pengambilan ubat adalah baik tetapi kawalan
glisemik adalah buruk. Hasil kajian juga menunjukkan kos penjagaan kesihatan
langsung total adalah berpunca terutama daripada kos perubatan langsung dan pesakit
kurang berpuas hati dengan penjagaan farmaseutikal pada tahap asas.  Analisis ukuran
berulangan menunjukkan penambahbaikan yang signifikan dalam skor pengetahuan,
sikap, praktis dan KAP total, HRQoL, kepatuhan pengambilan ubat dan hasil akhir
klinikal, kos penjagaan kesihatan langsung dan kepuasan pesakit pada setiap susulan
(p<0.001) selepas intervensi. Berbanding dengan kumpulan kawalan, pesakit dalam
kedua-dua kumpulan ujian menunjukkan tahap yang tinggi bagi pengetahuan [skor min
±sd (Kumpulan Kawalan (CG): 5.58±1.81; Kumpulan Ujian 1 (T1G): 13.18±1.57 dan
Kumpulan Ujian 1 (T2G): 15.59±.72)], sikap positif [skor min ±sd (CG: 10.86±1.66;
T1G: 13.04±1.37 dan T2G: 13.76±1.40)] dan praktis yang baik [skor min ±sd (CG:
6.86±1.08; T1G: 8.00±1.05 dan T2G: 9.47±.98)] pada susulan keempat, dan HRQoL
mereka bertambah baik secara konsisten dengan peningkatan besar pada susulan
keempat berbanding dengan tahap asas [skor median (CG: -3.16 berbanding -2.50; T1G:
-2.56 berbanding -2.61 dan T2G: -2.26 berbanding -2.30)], dan oleh itu memperbaiki
kualiti hidup umum mereka. Begitu juga, kepatuhan terhadap ubat [kepatuhan min ±sd
(T1G: 96.53±1.04%; T2G: 97.68±.74% dan CG: 85.02±3.46%)] dan kawalan glisemik
[median FBG, PPBG dan HbA1c (CG: 155, 186 dan 7.40%; T1G: 122, 148 dan 6.90%,
dan T2G: 119, 145 dan 6.40%, masing-masing)] telah diperbaiki secara konsisten dalam
kedua-dua kumpulan ujian dengan kepatuhan dan kawalan glisemik yang maksimum
pada susulan keempat. Walau bagaimanapun, terdapat penurunan kos penjagaan
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kesihatan langsung yang agak besar bagi pesakit dalam kedua-dua kumpulan ujian
sepanjang susulan dengan penurunan yang besar pada susulan keempat  [kos median
dalam matawang Nepali (CG: 1851.50; T1G: 1020.00 dan T2G: 900.00); 1 USD = 73.38
Nepali rupees], dan mereka lebih berpuas hati dengan program penjagaan farmaseutikal
dengan skor kepuasan yang lebih tinggi pada susulan keempat [skor median (CG: 47.74;
T1G: 68 dan T2G: 73)]. Oleh itu intervensi penjagaan farmaseutikal menunjukkan hasil
akhir yang positif bagi pesakit diabetes dari segi penambahbaikan pengetahuan, sikap
dan praktis, HRQoL, kepatuhan terhadap pengambilan ubat dan hasil akhir klinikal,
kepuasan dan pengurangan kos penjaagaan kesihatan langsung.
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IMPACT ASSESSMENT OF PHARMACEUTICAL CARE INTERVENTION ON
NEWLY DIAGNOSED DIABETES MELLITUS PATIENTS IN A TERTIARY
CARE HOSPITAL OF A SUB METROPOLITAN CITY OF WESTERN NEPAL
ABSTRACT
Poor socioeconomic status and lack of knowledge regarding disease are the major
hurdles to be addressed in management of the disease. Therefore, a randomised control
trial (RCT) study was conducted in five phases with the objectives of evaluating the
impact of pharmaceutical care intervention on knowledge, attitude and practice (KAP),
health-related quality of life (HRQoL), medication adherence and clinical outcomes,
direct healthcare costs and satisfaction of newly diagnosed diabetes mellitus patients in a
tertiary care hospital. A sample size of 162 patients was selected over 6-months duration
(from July 2010 to December 2010) and randomization was done by 1:1:1 in three
parallel groups: control group (n= 54), test 1 group (n= 54) and Test 2 group (n= 54).
Interventions were carried out with the used of specially designed educational materials
and tools. Descriptive and inferential statistics were performed in each part of the study.
Appropriate non-parametric tests such as Kruskal-Wallis, Mann-Whitney U, Friedman
and Wilcoxon signed rank tests (p≤0.05) have been used to find out the differences
while Spearman order correlation test (p≤0.05) was used to find out the association
among different dependent and independent variables. Patients’ age, monthly income,
gender, education and occupation were significantly associated with their knowledge,
attitude and practice scores about diabetes and its management. Patient’s HRQoL and
satisfaction scores were negatively associated with their age while age, education and
occupation of the patients were the significant predictor of patient’s medication
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adherence. At baseline, patients had poor knowledge, practice but relatively better
attitude regarding diabetes and they perceived their present quality of life as ‘bad’. The
medication adherence of the patients was considerable but they had poor glycaemic
control. Total direct healthcare costs of patients were mainly attributable to direct
medical costs, and patients were ‘least satisfied’ with pharmaceutical care at baseline. A
repeated measure analysis showed significant improvement in knowledge, attitude,
practice and KAP scores, HRQoL, medication adherence and clinical outcomes, direct
healthcare costs and satisfaction of the patients in their each follow-up (p<0.001)
following intervention. Compared to control group, patients of both test groups showed
high degree of good knowledge [mean score±sd (CG: 5.58±1.81; T1G: 13.18±1.57 and
T2G: 15.59±.72)], positive attitude [mean score±sd (CG: 10.86±1.66; T1G: 13.04±1.37
and T2G: 13.76±1.40)] and good practices [means score±sd (CG: 6.86±1.08; T1G:
8.00±1.05 and T2G: 9.47±.98)] at fourth follow-ups, and their HRQoL consistently
improved with considerable improvement at the fourth follow-ups than baseline [median
score (CG: -3.16 vs. -2.50; T1G: -2.56 vs. -2.61 and T2G: -2.26 vs. -2.30)], and hence
improved their general quality of life. Similarly, medication adherence [mean
adherence±sd (T1G: 96.53±1.04%; T2G: 97.68±.74% and CG: 85.02±3.46%)] and
glycaemic control [median FBG, PPBG and HbA1c (CG: 155, 186 and 7.40%; T1G:
122, 148 and 6.90%, and T2G: 119, 145 and 6.40%, respectively)] were improved in
both test groups consistently with maximum adherence and glycaemic control at fourth
follow-ups. However, there were considerable reduction in total direct healthcare costs
of patients in both test groups throughout with high reduction at the fourth follow-ups
[median costs in Nepali rupees (CG: 1851.50; T1G: 1020.00 and T2G: 900.00); 1 USD
= 73.38 Nepali rupees], and they were more satisfied with pharmaceutical care program
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with greater satisfaction scores at fourth follow-ups [median score (CG: 47.74; T1G: 68
and T2G: 73)]. Thus, pharmaceutical care intervention showed positive outcomes for
diabetes mellitus patients in terms of improving their knowledge, attitude and practice,
HRQoL, medication adherence and clinical outcomes, satisfaction and minimizing their
direct healthcare costs.
1CHAPTER 1
GENERAL INTRODUCTION
1.1 INTRODUCTION
1.1.1 Background of diabetes mellitus
Diabetes has been recognised as a devastating and deadly disease for more than 2000
years. It was one of the first diseases described in an Egyptian manuscript in 1500 BC
mentioning ‘too great emptying of the urine’. Around the same time, Indian physicians
also identified the disease and named it as ‘madhumeha’ or ‘honey urine’ and described
‘a mysterious disease causing thirst, enormous urine output and wasting away of the
body with flies and ants attracted to the urine of the people’ (Das & Shah, 2011). The
Greek Appollonius of Memphis first used the term ‘diabetes’ or ‘to pass through’ in
230 BC. The British surgeon John Rolle added the term ‘mellitus’ or ‘from honey’ to
diabetes in the late 1700s and separated the condition named diabetes insipidus, which
was also associated with frequent urination (MacCracken & Hoel, 1997).
Dr. Thomas Willis, a London-based physician, determined whether his patients
had diabetes or not by sampling their urine in the 17th century. According to him, if urine
had a sweet taste he would diagnose them with diabetes mellitus – "honeyed" diabetes.
This method of monitoring blood sugar became very popular and remained unchanged
until the 20th century. Different measures were tried in-between but effective treatment
was not developed until the early part of the 20th century. Sushruta, Arataeus and Willis
2were the early pioneers in the treatment of diabetes. Greek physicians used to prescribe
exercise preferably on horseback to employ moderate friction and alleviate excess
urination. There were different forms of remedy suggested for the therapy of diabetes
including wine, overfeeding to compensate for loss of fluid weight, starvation diet,
potato therapy and oat cure in olden days (Das & Shah, 2011). In 1913, scientist Allen,
after three years of diabetes study, published a book named ‘Studies Concerning
Glycosuria and Diabetes’. This book encouraged scientists and doctors to develop
therapies for diabetes patients.
In recent decades, the medical profession has advanced drastically and new
technologies and medicines have been launched to treat heath-related problems, and to a
certain extent this profession has taken up the challenges, but still there are many
unresolved problems regarding patients' response towards therapy and better therapeutic
outcomes resulting poor patients’ satisfaction and high economic burden on them. These
problems may be due to low patient involvement in their therapy, low level of their
knowledge and awareness about their problem and sometimes poor healthcare facilities.
Such problems become more challenging mainly in chronic disease conditions that
require a long-term treatment strategy and special care and attention for the patient's
benefit and a better therapeutic result.
Diabetes mellitus (DM) is a chronic disease condition with a rapidly increased
prevalence and has become a serious healthcare challenge. At one time, this disease was
considered as a problem of high-income countries (Balabanova et al., 2009), but now it
is also growing rapidly even in low-income countries, mainly due to the change in
lifestyle pattern, urbanisation and intake of high dietary fats (Moodley & Rambiritch,
32007). Increased incidence of diabetes has not only produced a clinical burden but also a
social and economical burden (Kapur, 2007). Poor socioeconomic status and illiteracy
leading to a lack of knowledge about the disease are the major hurdles in management of
this disease (Mehta et al., 2006).
Diabetes mellitus is a heterogeneous disorder characterised by a varying degree
of insulin resistance and insulin deficiency, which leads to disturbances in glucose
homeostasis. It is commonly associated with prolonged ill-health and premature death.
Chronic hyperglycaemia may lead to long-term complications that affect several organ
systems and may lead to poor quality of life. These complications may cause disability
and deformities among various organs. The mortality rate in patients with DM may be
up to 4-5 times higher than in persons without the disease (Morgan et al., 2000).
Diabetes is also the leading cause of stroke, renal failure, blindness and leg amputation
in adults in developed countries (Centers for Disease Control and Prevention, 2011).
Patient knowledge of diabetes mellitus can assist in early detection of the disease
and reduce the incidence of complications. The management of diabetes and its
complications not only depends on drug therapy but also on physical exercise, controlled
diet and other lifestyle modifications. Unless education is imparted and awareness is
created among people, it is difficult to control the prevalence of diabetes. Diabetes
education and awareness and improving motivation for self-care not only enhance care
and reduce the burden of complication but also indirectly reduce the overall economic
cost of diabetes (Kapur, 2001). Comprehensive patient education about diabetes and
self-care skills is the cornerstone therapy for diabetes patients to attain tight glycaemic
control (Asha et al., 2004).
41.2 Epidemiology of diabetes mellitus
1.2.1 Global scenario of diabetes mellitus
Diabetes is a serious condition not only for the individual, but also for society as a
whole. Almost every country is under the burden of diabetes, which is considered a
major public health problem. Diabetes is a metabolic syndrome, which if left untreated
may lead to long-term life-threatening complications and premature death (Roglic et al.,
2005).
The prevalence of diabetes has increased globally over the past two decades.
Diabetes is accepted as the fourth- or fifth-leading cause of mortality among various
diseases worldwide (International Diabetes Federation, 2011). Worldwide, several
reports have been published on the prevalence of diabetes. In developed countries, the
age group over 65 reflects the highest prevalence for the disease whereas in the
developing world, greater prevalence occurs in the 45-64 years age-group (Wild et al.,
2004). Diabetes currently affects 150 million people around the world and this number is
expected to increase to 300 million by 2025 (King et al., 1998). The projected estimation
reported by World Health Organization (WHO) and International Diabetes Federation
(IDF) about the global prevalence of diabetes was 2.8% in 2000, and it would be
increased to 4.4% in 2030 (Wild et al., 2004), and 366 million in 2011 and it is expected
to be increased to 552 million by 2030 (International Diabetes Federation, 2011)
respectively. The five countries with the highest diabetes prevalence in 2010 were Nauru
(30.9%), United Arab Emirates (18.7%), Saudi Arabia (16.8%), Mauritius (16.2%) and
Bahrain (15.4%) (Shaw et al., 2010). The United State of America (USA) was the
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2010 and it is expected to increase to 36 millions by 2030 (Shaw et al., 2010).
Developing countries will be hit the hardest by the growing diabetes epidemic.
Type 2 diabetes is more common in developing countries accounting for 90-95% of total
cases (Mohan et al., 2007). An aging population, a shift towards a more sedentary
lifestyle, increasing numbers of overweight and obese people, unhealthy diet and
growing urbanisation are possible factors contributing to this alarming increase of
diabetes prevalence (Amos et al., 1997; Zimmet et al., 2001). The incidence rate of
diabetes is much higher in developing countries (170%) compared to developed
countries (47%) (Zafar et al., 2011). Approximately 2-5% of adult populations located in
industrialised countries are affected by diabetes (Atak & Arslan, 2005). The prevalence
rate of diabetes is higher in the Asian nations. Approximately 50% of total global
diabetes populations are located in Asian countries including Indian, China and Nepal.
Among the top ten leading countries in terms of diabetes burden in the world, the top
five are Asian countries, in which India (87 million) and China (62.6 million) are
expected to be lead in terms of number of people with diabetes mellitus by 2030
(Cockram, 2000; Wild et al., 2004; Roglic et al., 2005; Mohan et al., 2007).
1.2.2 Prevalence of diabetes mellitus in Nepal
Nepal is located in between India and China. It is surrounded with hills and mountains
and is nearly 500 miles long and 110 miles wide with a population of 28 million
(Ministry of Health and Population, 2011). The country is divided into three
geographical areas, the flat ‘Terai planes’ in the south, the ‘Central hills’ and the ‘High
6Himalayas’ in the north. This division has isolated the rural areas from the central areas
and has hindered the development of transportation, communication and health facilities.
In addition, about 90% of the population lives in rural areas (Singh, 2004).
The data suggest the percentage of diabetes dominancy in urban and rural areas
is 25.9% and 3.1% respectively (Singh & Bhattarai, 2003). According to the Nepal
Diabetes Association (NDA), approximately 15% of people more than 20-years old and
19% of people more than 40 years of age are affected with diabetes in urban areas
(Bhattarai & Singh, 2007). As per the WHO estimation, more than 436,000 people are
affected with diabetes in Nepal and the number is expected to increase to 1,328,000 by
2030 (Wild et al., 2004). The prevalence rate of type 2 diabetes mellitus and impaired
fasting glucose have been reported as being about 9.0% and 19.2% respectively from
one study conducted in a semi-urban population of Nepal (Ono et al., 2007). A recent
study from Nepal also expected the prevalence of diabetes to be increased by 17% in
2020 (Dulal & Karki, 2009). The reasons behind the high prevalence of DM in Nepal are
identified as low literacy, increased body weight due to intake of more fatty food, low
physical activity and change in lifestyle (Upadhyay et al., 2008; Maskey et al., 2011).
1.3 Impact of diabetes mellitus and its complications
Diabetes affects persons of all ages, sexes and races. The disease reduces both a person’s
health-related quality of life (HRQoL) and life expectancy and imposes a large
economic burden on their families, healthcare system and the nation. Diabetes is
associated with serious long-term effects, which could have a huge impact on the quality
of life of patients, especially when both micro-vascular and macro-vascular
7complications are present. The risk factors for developing micro-vascular complications
include duration of diabetes, glycaemic control and hypertension. The strongest risk
factors for the development of macro-vascular complications include hypertension,
hyperlipidaemia, smoking and albuminuria. Micro-vascular complications affect the
small blood vessels and comprise of retinopathy, nephropathy and neuropathy. Macro-
vascular complications encompass cerebrovascular disease, ischaemic heart disease and
peripheral arterial disease (Marshall & Flyvbjerg, 2006). The risk for macro-vascular
diseases tend to manifest in people with type 2 diabetes more than those diagnosed with
type 1 diabetes, as hyperglycaemia contributes to the development of these
complications. There is evidence that has proved the relationship between the degree of
glycaemic control and the development of these complications (Klein & Klein, 1998;
Stratton et al., 2000; American Diabetes Association, 2002a; Nordwall et al., 2009;
Huang et al., 2011).
The incidence of mortality and disability due to diabetes is rising drastically all
over the world. People with diabetes have an increased risk of mortality and morbidity
compared with their non-diabetic counterparts. As pointed out by Mohan et al. in the
2009 the WHO report, there are about five times as many deaths indirectly attributable
to diabetes (Mohan & Pradeepa, 2009). The death rate of men living with diabetes is 1.9
times and for women 2.6 times more than men and women without diabetes respectively
(Lee et al., 2000). Premature mortality caused by diabetes results in an estimated 7 to 14
years of life lost compared to their non-diabetic counterparts (Narayan et al., 2003a;
Manuel & Schultz, 2004; Andrade, 2010). The majority of the diabetes-related deaths
are due to cardiovascular and cerebrovascular diseases and end-stage renal diseases
8(Cusick et al., 2005). It is estimated that each year, approximately 3.8 million people die
from diabetes-related complications worldwide (International Diabetes Federation,
2006).
In addition to the morbidity and mortality, diabetes exerts a heavy economic
burden on the society. This burden is related to health-system costs incurred by society
in managing the disease, indirect costs resulting from productivity losses due to patient
disability and premature mortality, time spent by family members in seeking care of the
patient and intangible costs (psychological pain to the family and loved ones). It was
estimated that the total global cost to manage diabetes was USD 376 billion in 2010 and
it is expected to increase to USD 490 billion in 2030. Globally, 12% of the health
expenditure and USD 1330/person were anticipated to be spent on diabetes management
during the year 2010. This expenditure may fluctuate by region, age, gender and
country’s income. This data shows the huge impact on a nation’s economy. By looking
at these results, there is a need for urgent measures for better understanding of the
problem and novel strategies for prevention and treatment of the disease (Zhang et al.,
2010).
1.4 Concept of pharmaceutical care vs. Medication therapeutic management
Diabetes mellitus is spreading like a slow poison all over the world and causing
complications to the sufferer and affecting their quality of life and increasing the
economic burden. An individual suffering from type 2 DM is responsible for
himself/herself to a large extent since this disease is related to lifestyle and dietary
habits. However, development of type 1 diabetes mellitus is related with autoimmune
9destruction of the pancreatic β-cells, due to which there is absolute deficiency of insulin
in the body. Quite often patients do not adhere with their pharmacological (medication)
and non-pharmacological (lifestyle modification, dietary habits and importance of
recommended physical activities) treatments that are required to achieve the desired
metabolic control and thus minimise the emergence of micro- and macro-vascular
complications. Such problems can be avoided by increasing medication-adherence and
adopting appropriate non-pharmacological measures, in which the pharmacist can play
an important role through a well-structured pharmaceutical care (PC) programme
(Machado-Alba et al., 2011).
Pharmaceutical care involves identifying, resolving and preventing drug-related
problems. It is well understood that the pharmacist deals with medicines all the time.
Pharmaceutical care was the first integrated philosophy of pharmacy practice to combine
the expertise of the pharmacist with influencing prescribing and evaluating the drug
regimen on one side and medication counselling on the other side to improve the
patients’ therapeutic outcomes, including quality of life. The role and contribution of the
pharmacist in the healthcare system to achieve therapeutic outcome was developed by
Hepler and Strand in 1990 (Hepler & Strand, 1990). According to them, ‘pharmaceutical
care practice involves direct interaction between the pharmacist and the patient, with
responsible provision of drug therapy in order to achieve definitive outcomes that
improve a patient’s quality of life and promote disease management’. These outcomes
are: (1) cure of disease; (2) eradication or decrease of patients’ symptomatology; (3)
arresting or slowing of disease process; or (4) preventing a disease or symptomatology
(Hepler & Strand, 1990). Later, the philosophy of Hepler and Strand was refined by
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Cipolle et al. and they said that ‘it is a patient-centred practice’ (Cipolle et al., 2004). In
both these definitions, the emphasis is on the patient and the pharmacist’s responsibility
to ensure good quality of care to the patient and to achieve better patient outcomes. The
pharmacist’s role has evolved over the twentieth century from mainly being product
focused, preparing and dispensing drugs, into a more patient-orientated care provider,
and pharmaceutical care may be the target for the pharmacy profession worldwide.
Although, pharmaceutical care is delivered by many different healthcare professionals,
the pharmacists can be regarded as specialists in this practice as their focus is on
pharmacology and pharmacotherapy, important skills for providing pharmaceutical care.
Pharmaceutical care deals with the way people should receive and use
medications and instructions for the use of medicines. It also deals with the
responsibilities, medication surveillance, counselling and outcomes of care.
Pharmaceutical care can be achieved through the performance of a team of healthcare
professionals including the pharmacist, doctors, nurses and technicians. This facilitates
good communication between the different members of the healthcare team and
continuity of care (Hepler & Strand, 1990; Palaian et al., 2005; Hudson et al., 2007).
However, the concept of Medication therapy management (MTM) is a distinct
service or group of services that optimizes drug therapy with the intent of improved
therapeutic outcomes for individual patients. Medication therapy management includes
five core components: a medication therapy review (MTR), personal medication record
(PMR), medication-related action plan (MAP), intervention and/or referral, and
documentation and follow-up. During the MTM session, the pharmacist identifies
medication-related problem(s) and determines appropriate intervention(s) for resolution.
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Often, the pharmacist collaborates with other health care professionals to resolve the
identified problem(s) (American Pharmacist Association and National Association of
Chain Drug Store Foundation, 2008).
1.5 Concept of pharmaceutical care in Nepal
It is evident that the pharmaceutical care concept is still in the theoretical stage in Nepal
and the practice is non-existent. A thorough literature survey showed that studies are
lacking in the area of pharmaceutical care in Nepal. In Nepal, pharmacists are still
considered as 'medicine sellers' to the public and they are more product oriented rather
than patient oriented (Khanal et al., 2010). Pharmacists are still not focused on their role
in patient care in the present healthcare system of Nepal. A review by Bhandari and
associates (2006) reported that pharmacists in the country were involved in providing
drug information and research work in few Nepali hospitals (Bhandari et al., 2006)
suggesting an emerging scope, although it is not substantial.
In the Nepalese context, pharmacists focus on the industrial sector or the
teaching profession, and then open their ‘medicine shops’ after finishing their pharmacy
education. Recently, in 2010, the pharmacy education system of Nepal put a step
forward in pharmacy education and started the Pharm.D program in Kathmandu
University with the objective of providing better knowledge and more recognition and
opportunity to the pharmacy graduates in the healthcare sector (Bhuvan et al., 2011). By
this program, the education system of Nepal has provided a clear understanding to the
pharmacists on their responsibilities as a healthcare professional and their contribution
as a pharmacist in patient care.
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The present study also focused on the contribution of the pharmacist in patient
care through the pharmaceutical care program. This study may circulate the clear
concept of pharmaceutical care among the Nepali pharmacists and their role in patient
care so that they become more patient-focused at the hospital and community level.
1.6 Pharmaceutical care and its importance in diabetes mellitus management
The need for intensive diabetes mellitus management is the subject of discussion and
debate, and it is clear that intervention programs to improve diabetes care and outcomes
are important (Gæde et al., 2003; Krass et al., 2007; Wubben & Vivian, 2008). People
with diabetes stay in the hospital much longer than the non-diabetic subjects and
therefore it is a major concern for the healthcare system. The healthcare system may
adopt certain approaches to minimise the patient stay in the hospital by improving their
symptoms. It has been reported that the frequency of hospitalisation of diabetes patients
are 1.5 times more and on an average 2.8 days longer than their non-diabetic
counterparts (Koproski et al., 1997; Puig et al., 2007).
The pharmacist's role through pharmaceutical care has come up with some
definite outcomes in the form of improved clinical outcomes (significant glycaemic
control), improved patient satisfaction, improved cost management and reduced hospital
stay (Singhal et al., 2002; Davis et al., 2005; Scott et al., 2006; Krass et al., 2007;
Wubben & Vivian, 2008; Al Mazroui et al., 2009; Monte et al., 2009; Venkatesan et al.,
2012). Pharmacists are easily accessible to patients in comparison with other healthcare
professionals and therefore can provide better healthcare services to people with
diabetes. Diabetes patients who received monitoring by the pharmacist through the
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pharmaceutical care program reduced glycated haemoglobin (HbA1c) level by an
average 1.9% in a six month period (Rothman et al., 2003). Similarly, people with
diabetes experience greater satisfaction with their care when they received proper
diabetes education, proper medication counselling and instruction on diet and exercise
from their pharmacists (Singhal et al., 2002; Cranor et al., 2003; Zanetti et al., 2007;
Sriram et al., 2011). A study reported that diabetic patients are able to reduce their
HbA1c level to 7% or below and decrease their unscheduled clinical visits if they are
provided proper physician supervision and systematic monitoring by the pharmacist
(Irons et al., 2002). Diabetes carries a huge medical cost for the patient and their family
members and decreases the productivity rate. Studies from different countries have
stated that a reduction in medical cost and an increase in their productivity rate can be
achieved by improving the patient’s symptoms and reducing the risk rate through a
structured pharmaceutical care program (Cranor et al., 2003; Garrett & Bluml, 2005).
1.7 Problem statement
Diabetes is an emerging health problem in Nepal. The number of people with diabetes is
increasing day by day. It is difficult to estimate exact number of diabetic patients due to
a lack of proper research and documentation in Nepal. Moreover, many diabetes patients
are not aware of their problem due to lack of knowledge and awareness (Mehta et al.,
2006; Upadhyay et al., 2008). They are also not getting effective and appropriate
treatment and advice due to lack of proper healthcare facilities. The second important
aspect is the dietary habit, which is unique in Nepal and they still have the old traditional
concept. Lack of proper knowledge about the disease and poor dietary education has
resulted in late detection of the disease by the patients, thus this has been a burning
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problem. Therefore, looking at these aspects, the study has concluded the following
problems:
Past evidence suggests a lack of knowledge and awareness about diabetes among
the Nepali diabetic population and unavailability of systematic valid plans to cope with
such problems. Similarly, there has been a dearth of data and research to assess the
health-related quality of life (HRQoL) of diabetes patients and no research has been
done to date in Nepal to quantify HRQoL due to lack of a valid instrument to measure it
in the native language. In addition, there is no systematic approach in Nepal to increase
patient adherence to their medication, resulting in poor glycaemic control in diabetes
patients. Furthermore, to the best of my knowledge, there has been no focus on direct
health-care costs (direct medical and non-medical cost) from patients prospective and
there is a scarcity of valid research and data related to it in the country as well.
Added to the above issues, information is lacking to establish the association
between provided patient-care and patient satisfaction in diabetes management in the
Nepali healthcare system. Moreover, pharmacist involvement in patient care is still not
recognised in the Nepali healthcare system. In addition, the low literacy rate (age group
15+years, total literacy rate (%) 2008/09 was 56%) in the country (Ministry of
Education, 2010) still raises concerns over patient’s knowledge and acceptance of the
PC concept. Although, the existing scarcity of data, a quick reflection over the health
care situation and health seeking behaviours of the layman, raises much concern over the
‘health concern’ among the citizens. Since diabetes is a chronic condition and may not
present much of its symptoms at the initial stages one might have a poor ‘health
concern’ over the condition especially in a country where the vast majority of the
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population is illiterate. In addition, one study established a relationship between
economic condition, educational status and health-seeking behaviour of Nepali citizens
(Subba, 2004). These entire observations make the necessity for need of in-depth study
in relevant domains of diabetes research.
1.8 Rationale of the study and its importance
The pharmaceutical care concept and the role of the pharmacist in patient care is mainly
popular in developed countries and several studies have been done in related areas
(Clifford et al., 2002; Strand et al., 2004; Clifford et al., 2005; Davis et al., 2005; Al
Mazroui et al., 2009; Correr et al., 2009; Neto et al., 2011). The total number
pharmacists registered with Nepal Pharmacy Council till year 2010 were 1690 among 28
million population of the country, with the pharmacist-to-public ration of 1:16,568
(Nepal Pharmacy Council, 2010). But the pharmacist involvement in patient care is still
not well recognized in developing countries like Nepal where the resources are limited
and pharmacist are still recognized as mere ‘drug seller’ (Palaian et al., 2005; Khanal et
al., 2010). No research has been done to date that has focused on the pharmacist's role in
patient care through a pharmaceutical care concept in healthcare services in Nepal. Due
to limited resources and increasing population, the health-related problems like
cardiovascular diseases, hypertension and diabetes have increased tremendously leading
to long-standing complications and more mortality and morbidity. The reasons may be
linked to low literacy, low knowledge and poor awareness about the disease condition in
patients. Lifestyle changes, obesity, poor dietary habits (intake of more fatty food) and
low physical activity are making these problems more aggressive and longer standing
(Mehta et al., 2006; Upadhyay et al., 2008; Maskey et al., 2011).
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Poor healthcare facilities combined with low knowledge and awareness in
patients causes more patient’s non-adherence to their medications leading to poor
therapeutic outcomes (Whitley et al., 2006; Al-Qazaz et al., 2011) and requiring more
hospital services. Together, this produces more economic burden on patients and their
family members. Such problems become more complex in chronic disease conditions
like diabetes where patients get overburdened with prescribed medication. Therefore, it
requires a bidirectional approach. First and foremost, the diabetes educational program
about the ways to prevent the disease should be organised on a large scale. Secondly, the
diabetes patients should get proper treatment, counselling and advice as per their need.
Early detection of DM can be helpful in managing the disease by exercise and controlled
diet, which directly affects the patient’s economic burden. Education and counselling
would be helpful for the patient to maintain their blood glucose level, which directly
affects the patient’s quality of life. Very little work has been done in Nepal so far in this
regard.
Therefore, by conducting this study, we will understand better about diabetes
patients’ knowledge and awareness of their disease and its effect on their attitude and
practice. It also provides insight on the impact of diabetes on patient’s health-related
quality of life, medication adherence and clinical outcomes with emphasis of direct
healthcare costs and satisfaction level of patients.
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1.9 Contributions of the study findings
It was anticipated to have considerable contributions during beginning of the study.
Those anticipated outcomes of the study during initiation were helpful to establish the
importance of the pharmaceutical care concept in the healthcare system of Nepal where
previously no studies have addressed this concept. It was also anticipated that the
present study would be beneficial for the diabetes patients to improve their knowledge
and awareness, which will help them to improve their attitude and practice and hence
nourish their quality of life. The study will also provide a valid method to improve
therapeutic outcome and decrease economic burden. This study might also convey the
message to other healthcare professionals that the pharmacist is also an important
member of the healthcare team and can play a major role in patient care.
In addition, this study was expected to contribute to a better understanding of
future pharmacists about their role and place in the healthcare system and it may divert
their thinking to become more patient oriented. This study is an attempt to sensitise the
government and provide validated information to government officers and policy makers
so that they would have a better idea about the pharmacist's place in the healthcare
system and their role in patient care. The findings could also set up a good platform for
future researchers and provide a well-established module and primary data for further
research on a large scale. This study would develop the appropriate diabetic kit that can
be used to educate the patients (especially uneducated patients) about their disease
through live demonstrations for better understanding of the patients.
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1.10 Study objectives
Keeping the vision of the research study shown in Figure 1.1, the overall research
objectives are as follows:
1.10.1 General objective
The general objective of the research is to evaluate the impact of a pharmaceutical care
intervention targeted at newly diagnosed diabetes mellitus patients in terms of
knowledge, attitude, practice, health-related quality of life, medication adherence and
clinical outcomes, direct healthcare costs and patient’s satisfaction.
1.10.2 Specific objectives
The various specific objectives are as below:
1. To describe the demographic distribution of newly diagnosed diabetes mellitus
population with respect to their age, gender, ethnicity, education level and occupation.
2. To evaluate the impact of pharmaceutical care intervention provided by the
pharmacist in terms of knowledge, attitude and practice of patients about diabetes and its
management.
3. To quantify the impact of pharmaceutical care intervention provided by pharmacist in
terms of health-related quality of life outcomes of diabetes mellitus patients.
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Figure 1.1 Vision of the overall research
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4. To evaluate the impact of pharmaceutical care intervention provided by pharmacist in
terms of medication adherence and clinical outcomes (i.e. glycaemia and blood pressure
control), direct healthcare costs and satisfaction of diabetes mellitus patients.
1.11 Thesis overview
This thesis consists of seven chapters including this chapter (general introduction).
Chapter 2 is related to a literature review and the conceptual framework. This chapter
gives brief information related to diabetes and its management followed by in-depth
reviews of literature related to individual study objectives with a suitable definition of
terms used wherever necessary. This chapter will be ending with the study's conceptual
framework, research questions and hypothesis with a brief conclusion about significant
gaps in diabetes care that need to be minimised with pharmacist intervention.
Chapter 3 will be basically discussing about general methodology used in present study.
This chapter will highlight the detail explanation about the methodology used in present
research study with description of different study tools and questionnaire formulation.
This chapter also talks about how the intervention and reinforcement program was
conducted for diabetes patients with a brief note on a pilot study conducted for
methodology and tools' validation.
Chapter 4 is about the impact assessment of pharmaceutical care intervention on the
knowledge, attitude and practice of newly diagnosed diabetes patients in tertiary care
hospital. This chapter includes a detailed analysis of diabetes patients’ knowledge,
attitude and practice (KAP) about diabetes and its management with emphasis of the
impact of the pharmacist-provided pharmaceutical care intervention on diabetes patients’
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KAP. The chapter will be ending with detail discussion on study findings and
conclusion.
Chapter 5 describes the impact assessment of pharmaceutical care intervention on
health-related quality of life of newly diagnosed diabetes patients. This chapter provides
a detailed description and analysis of diabetes impact on general and overall health-
related quality of life of diabetes patients with emphasis on the impact of pharmaceutical
care intervention on health-related quality of life of diabetes patients. The chapter ends
with a discussion on the study findings and the conclusion.
Chapter 6 illustrates the impact assessment of pharmaceutical care intervention on
medication adherence and clinical outcomes, direct healthcare costs and satisfaction of
newly diagnosed diabetes patients. This chapter focuses initially on the pattern of
medication adherence and clinical outcomes of diabetes patients, assessment of direct
healthcare costs of patients and their satisfaction with an emphasis on the pharmacist
intervention on these outcomes. The chapter ends with a detailed discussion on findings
related to patients’ medication adherence and clinical outcomes, direct healthcare costs
and satisfaction along with a brief conclusion.
Chapter 7 is the thesis conclusion and also the final chapter of this thesis. This chapter
starts with a summary of the study followed by study limitations along with a set of
recommendations. The chapter ends by highlighting suitable future research and the
conclusion.
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CHAPTER 2
LITERATURE REVIEW AND RESEARCH CONCEPTUAL FRAMEWORK
2.1 Definition of Diabetes mellitus
Diabetes mellitus (DM) represents a group of metabolic disorders and is characterized
by an increase in blood glucose level termed as ‘hyperglycaemia’. It is associated with
abnormalities in carbohydrate, fat and protein metabolism that results due to defects in
insulin secretion, insulin action or a combination of both. Several pathogenic factors are
responsible for abnormality in insulin secretion and insulin action, which range from
autoimmune destruction of pancreatic β-cells to abnormalities that result in resistance to
insulin action (World Health Organization & International Diabetes Federation, 2006;
American Diabetes Association, 2012).
2.2 Classification of diabetes mellitus
Based on the aetiology, most cases of DM falls into two category ‘Type 1 diabetes
mellitus’ and ‘Type 2 diabetes mellitus’. Apart from this gestational diabetes mellitus
(GDM) and diabetes due to drugs (Drug induced diabetes mellitus) and secondary to
other disease conditions related with pancreas like acute and chronic pancreatitis etc.,
are also rarely seen (American Diabetes Association, 2002b).
In case of Type 1 DM, there is absolute deficiency of insulin due to immune-
mediated destruction of the pancreatic β-cells. This type of diabetes is common in
children and adolescents and can be managed with combination of pharmacological and
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non-pharmacological agents like insulin, diet and exercise (Franz et al., 2004).
Autoimmune  destruction  of  the  β-cells  is  due  to  multiple  genetic predispositions
and environmental factors and are still not well defined (Åkerblom & Knip, 1998;
Visalli et al., 2003; Majeed & Mea, 2011). The patients with type 1 diabetes mellitus
require exogenous administration of insulin throughout their life for survival (American
Diabetes Association, 2012).
Type 2 DM is most common type of diabetes and mainly found in 90-95% of all
diabetes cases (American Diabetes Association, 2007). This type of diabetes is also
known as ‘non insulin dependent diabetes mellitus’ (NIDDM) or ‘maturity onset
diabetes in youth’ (MODY). Type 2 DM occur due to impaired insulin secretion and
insulin resistance of target tissues, mainly liver and skeletal muscles. Type 2 DM
patients are in general at an increased risk of developing macro-vascular and micro-
vascular complications (Triplitt et al., 2005; American Diabetes Association, 2012).
These days large number of people at younger age group is developing type 2 DM due
to obesity and sedentary lifestyle (Hu, 2003). It is known that about 80% of type 2 DM
are preventable by following a healthy lifestyle, physical activity, maintaining ideal
body weight and proper nutritional supplements (International Diabetes Federation,
2009).
Gestational diabetes mellitus (GDM) refers to the detection of glucose
intolerance first time during pregnancy. Insulin resistance during pregnancy is mainly
due to certain metabolic changes which increases insulin requirement and may lead to
hyperglycaemia or impaired glucose tolerance (IGT). Most of the time women revert
back to normal glucose tolerance after post-partum with a substantial risk (30-60%) of
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developing DM in later phase of the life (Centers for Disease Control and Prevention,
2011).
2.3 Clinical presentation of diabetes mellitus
Type 1 DM individuals are more often thin and prone to develop diabetic ketoacidosis
(DKA) due to insulin crisis, or under condition of severe stress with an excess of insulin
counter regulatory hormones. About 20-40% of patients with type 1 DM present with
diabetic ketoacidosis after several days of polyuria, polydipsia, fatigue, abdominal pain
and often with weight loss (Atkinson & Eisenbarth, 2001; Al Magamsi & Habib, 2004;
American Diabetes Association, 2007; Razavi, 2010). Commonly, patients of type 2 DM
may present with or without diabetes symptoms even though they carry the
complications indicating that they have diabetes since several years. Type 2 DM patients
may present with lethargy, polyuria, nocturia and polydipsia at diagnosis, and at times
associated with weight loss (Triplitt et al., 2005).
2.4 Diagnosis of diabetes mellitus
Normally the diagnosis of diabetes is performed only when the patient shows one or
more usual symptoms of diabetes. Early diagnosis can render better management of
diabetes and thus delaying the long term complications. The level of blood sugar is
measured in venous blood sample. The diagnosis of diabetes is performed on the basis of
the criteria given by American Diabetes Association (American Diabetes Association,
2007).
